This website uses cookies in order to maximize its functionality and to provide you with better user experience.

Closing this window or continuing to navigate in the website means that you understand and accept the use of cookies in the website. 

Close
Roche Navigation Menu Roche4Med : Roche4Med
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Products
      Products Overview
    • Congresses & Events
      Congresses & Events Overview
    • Comprehensive Genomic Profiling
      Comprehensive Genomic Profiling Overview
    Close

    1 - of results for ""

    No results

    Are you registered? Register now to view Roche scientific information for HCPs!

    • Safety Information

      Read more

    • Tecentriq®
    • Mechanism of Action
    • Clinical Data
      • Non-small cell lung cancer
    • Dosing & Administration
    • AR Management
    • Resources
      • Professional Resources
      • Congresses
    • Safety Information
    • References
    • More
      • Mechanism of Action
      • Clinical Data
      • Dosing & Administration
      • AR Management
      • Resources
      • Safety Information
      • References

    You are here:

    1. Products
    2. Tecentriq®
    3. Safety Information

    Important Safety Information

     

    This guide is intended to provide information about the management of certain important identified risks when prescribing Tecentriq for urothelial carcinoma and NSCLC, including immune-mediated pneumonitis, hepatitis, colitis or diarrhea, endocrinopathies, , other immune-mediated adverse reactions involving a major organ, infections and infusion related reactions.

    All patients receiving treatment with Tecentriq must be given Patient Brochure and Patient Alert Card by their healthcare professional to educate them about the symptoms of immune-mediated adverse reactions and the need to report them to their treating doctor immediately. Treating doctors should also advise their patients to keep the Patient Alert Card with them at all times and show it to any healthcare professional who may treat them.

    To obtain copies of the Patient Brochure and Patient Alert Card, please download or contact Roche Israel via Roche Israel website at http://www.roche.co.il/ 

    For more information, please refer to TECENTRIQ® prescribing information. 

    Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://www.gov.il/he/service/side_effects_reports or by referring to Roche Pharmaceuticals Israel Drug Safety in the following mail: israel.drugsafety@roche.com


    MatCode Approval No.: -1905-V2-3253

    Share
    Close

    Important notice!

    This website is intended for the use of healthcare professionals only, Please approve that you are a healthcare professional in order to continue using this website.

    Accept Cancel
    • © 2021 Roche Pharmaceuticals (Israel) Ltd.
    • 03.08.2020
    • Legal Information

    • Find us on YouTube